Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia

Published:2014-10-14 Issue:3 Volume:168 Page:395-404
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Sutton Rosemary¹,Shaw Peter J.²,Venn Nicola C.¹,Law Tamara¹,Dissanayake Anuruddhika¹,Kilo Tatjana²,Haber Michelle¹,Norris Murray D.¹,Fraser Chris³,Alvaro Frank⁴,Revesz Tamas⁵,Trahair Toby N.¹⁶,Dalla-Pozza Luciano²,Marshall Glenn M.¹⁶,O'Brien Tracey A.¹⁶

Affiliation:

1. Children's Cancer Institute Australia; Lowy Cancer Research Centre, UNSW; Randwick NSW Australia

2. Oncology Unit; The Children's Hospital at Westmead; Westmead NSW Australia

3. Royal Children's Hospital; Brisbane Qld Australia

4. John Hunter Children's Hospital; Newcastle NSW Australia

5. Women and Children's Hospital; Adelaide SA Australia

6. Kids Cancer Centre; Sydney Children's Hospital; Randwick NSW Australia

Funder

National Health and Medical Research Council

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.13142/fullpdf

Reference43 articles.

1. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group;Bader;Journal of Clinical Oncology,2009

2. Outcome of children who experience disease relapse following allogeneic hematopoietic SCT for hematologic malignancies;Bajwa;Bone Marrow Transplantation,2013

3. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study;Balduzzi;Lancet,2005

4. Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time;Balduzzi;Haematologica,2008

5. Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?;Balduzzi;British Journal of Haematology,2014

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pre-TCR-Targeted Immunotherapy for T-cell Acute Lymphoblastic Leukemia;2024-06-02

2. Intensified conditioning regimens with total marrow irradiation/etoposide/cyclophosphamide and busulfan/etoposide/cyclophosphamide overcome the impact of pre‐transplant minimal residual disease on outcomes in high‐risk acute lymphoblastic leukemia patients in complete remission;Cancer Medicine;2024-01

3. Anlotinib exerts an anti-T-cell acute lymphoblastic leukemia effect in vitro and in vivo;Cellular Signalling;2023-10

4. Immunophenotypic measurable residual disease monitoring in adult acute lymphoblastic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation;Frontiers in Oncology;2023-02-22

5. Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era;Frontiers in Pediatrics;2022-06-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3